the first years of payment by result negotiation TTPbr is more correlated to the cTTOT whereas in the last years is moving closer to the experimental one.

REFERENCES:

1. Martini N, Jommi C, Labianca R. (2015). Un nuovo modello di governance per il market access dei nuovi farmaci in oncologia. 1,7 -69.

2. Italian Medicines Agency (2015) – National Report on Medicines use in Italy. 33,18-89.

PP128 Regional Guidance On Spinal Cord Stimulation For Chronic Pain

AUTHORS:

Anna Cavazzana (anna.cavazzana@regione.veneto.it), Anna Redomi, Elena Poerio, Francesca Bassotto, Rita Mottola, Margherita Andretta, Giovanna Scroccaro

INTRODUCTION:

Chronic Pain (CP) is the uncontrolled pain that affects patients for a long time. CP can be caused by many conditions, sometimes still poorly understood, and its levels can vary from moderate to intense. The management of resistant CP requires a stepwise approach and spinal cord stimulation (SCS) could be considered an extreme strategy. With the aim of ensuring the economic sustainability, the Veneto Region usually establishes rigorous access criteria to high-cost medical devices through its Regional Technical Committee on Medical Devices (CTRDM) and a Health Technology Assessment (HTA) procedure.

METHODS:

The Regional Health Technology Assessment Unit (CRUF) conducted through Pubmed a literature review of randomized controlled trials, systematic reviews, meta-analysis on SCS published from March 2006 to February 2016. International and national clinical guidelines were included in the analysis as well. The regional multidisciplinary Working Group on CP, which involved local clinicians, pharmacists, clinical engineer and health economist, discussed the collected evidence by consensus. Final recommendations on the appropriate use were submitted to the CTRDM for final approval.

RESULTS:

The regional guidance describes the type of pain that can be treated with spinal neurostimulators and the criteria which determine the success of the test procedure. A comparative analysis of spinal neurostimulators available on the market and related patients eligibility criteria have been also included. Moreover, the guidelines stated a list of compulsory requirements in order to become a regional center authorized in performing spinal neurostimulation procedure. Finally, the document describes some indicators for appropriateness monitoring. The CTRDM approved the final version in October 2016.

CONCLUSIONS:

The regional guidance on SCS aims at ensuring the appropriate use of neurostimulators in patients affected by resistant CP. The strict monitoring of agreed indicators is essential for appropriateness and consequently the sustainability of medical devices expenditure throughout the Regional Health Service.

PP129 Methodological Issues With Assessing Newborn Screening Tests

AUTHORS:

Bing Guo (bguo@ihe.ca)

INTRODUCTION:

To outline the methodological issues associated with the assessment of newborn screening for severe combined immunodeficiency, which was conducted to address the policy question of whether this test should be added to an existing newborn screening panel.

https://doi.org/10.1017/S0266462317002823 Published online by Cambridge University Press